Oncotelic Therapeutics, Inc. (OTCQB: OTLC) today announced its inclusion in an editorial published by NetworkNewsWire, a communications platform specializing in financial news and content distribution. The article, titled "Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology," highlights how nanocarrier-based delivery systems are transforming cancer treatment. Oncotelic's Deciparticle platform exemplifies this progress by improving bioavailability and therapeutic index across multiple oncology drugs.
The advancement of Sapu-003, Intravenous Deciparticle Everolimus (Afinitor), into human trials underscores the company's innovation in drug delivery and its mission to enhance efficacy and patient outcomes. The editorial discusses how nanomedicine is redefining drug delivery, addressing challenges such as poor solubility, rapid clearance, and off-target toxicity that have historically limited the effectiveness of many anticancer agents.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company's mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents.
Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu's leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic's strategic position in oncology and rare disease therapeutics. The full press release is available at https://nnw.fm/L6Muy.
NetworkNewsWire is a specialized communications platform with a focus on financial news and content distribution. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, visit https://www.NetworkNewsWire.com.
